Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Tryptamine Therapeutics.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX healthcare leaders wear many hats in interconnected sector
Health & Biotech
ASX Quarterly Health Wrap: Bioxyne revenue up 77%, Radiopharm lists on Nasdaq
Tony's Takeaway
Tony’s Takeaway: New year nuggets for biotech-hungry investors
Health & Biotech
Health Check: Biotech partnership eyes Euro market expansion for Rett syndrome drug
Health & Biotech
Health Check: Joy as Mesoblast wins its first FDA approval for a stem-cell therapy after decades of trying
Health & Biotech
Positive interim results for Tryptamine’s trial of oral psilocybin to treat IBS
Health & Biotech
Tryptamine’s psilocin infusion study reveals solid results in obese
Health & Biotech
Could Trump’s second act boost these ASX psychedelic stocks?
Health & Biotech
Tryptamine completes psilocin-based IV-infusion study in obese subjects
Health & Biotech
Tryptamine’s world-first psilocin based IV-infusion meets key objectives in phase 1b study
Health & Biotech
Biocurious: From drug prices to efficiency drives, ASX biotechs await the ‘Trumpcare’ health fallout
Health & Biotech
Health Check: Actinogen powers ahead with key Alzheimer’s disease trial
Break It Down
Break it Down: Cash in the bag for Tryptamine Therapeutics
News
ASX Small Caps Lunch Wrap: (Super)markets fall on Aussie inflation data; goldies still gleaming
Health & Biotech
Tryptamine raises $6 million to advance world-first IV psilocin drug
News
Rise and Shine: Everything you need to know before the ASX opens
Stockhead TV
